ATAI AtaiBeckley Inc.
Price Chart
Executive Summary
AtaiBeckley Inc. reported its Q4 and full-year 2025 financial results, highlighted by a successful FDA End-of-Phase 2 meeting for BPL-003 in treatment-resistant depression, enabling Phase 3 initiation in Q2 2026. The company also announced positive Phase 2a results for EMP-01 in social anxiety disorder and extended its cash runway to early 2029 with $220.7 million in cash and short-term securities. However, net losses widened significantly due to a $530 million non-cash charge from the Beckley Psytech combination.
Key Financial Metrics
Actionable Insight
Investors should monitor upcoming clinical catalysts: BPL-003 Phase 3 initiation in Q2 2026, VLS-01 Phase 2 topline data in H2 2026, and BPL-003 Part 4 cohort data in Q4 2026. Despite strong cash runway and clinical progress, the massive non-cash loss may weigh on sentiment, though it does not reflect ongoing operating performance.
Key Facts
- FDA provided constructive feedback supporting Phase 3 initiation of BPL-003 for TRD in Q2 2026
- Phase 2a trial of EMP-01 in social anxiety disorder met primary safety endpoint and showed statistically significant efficacy (p=0.036)
- Cash, cash equivalents, and short-term securities totaled $220.7 million as of December 31, 2025, up from $72.3 million in 2024
- Net loss attributable to stockholders was $660.0 million for 2025 vs. $149.3 million in 2024, driven by $530 million in non-cash R&D acquisition expenses
- R&D expenses decreased slightly YoY to $53.1 million, while G&A expenses rose to $65.1 million due to combination-related costs
- Company expects cash runway into early 2029, covering key clinical readouts
Financial Impact
Significant non-cash charge of $530 million from in-process R&D related to Beckley Psytech combination; cash position increased by $148.4 million primarily from $291.1 million in equity proceeds
Risk Factors
- High cash burn rate: $102.7 million used in operations in 2025
- Clinical trial delays or failures in pivotal BPL-003 program could significantly impact valuation
- Equity dilution from $291.1 million in equity issuances may concern shareholders
- Reliance on successful integration and execution post-strategic combination
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3250955 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 3, 2026
10d ago
|
8-K
| $4.53 $4.50 | ▼ −0.66% | ▼ −1.06% | $3.92 (−13.47%) |
|
May 12, 2026
4w ago
|
Press Release
| $4.15 $4.24 | ▲ +2.17% | ▲ +1.59% | $3.92 (−5.54%) |
|
Apr 27, 2026
6w ago
|
Press Release
| $4.34 $4.33 | ▼ −0.23% | ▲ +0.25% | $3.92 (−9.68%) |
|
Apr 20, 2026
7w ago
|
144
| $4.87 $4.71 | ▼ −3.29% | ▼ −4.30% | $3.92 (−19.51%) |
|
Apr 8, 2026
9w ago
|
Press Release
| $3.76 $3.70 | ▼ −1.60% | ▼ −2.17% | $3.92 (+4.26%) |
|
Mar 24, 2026
11w ago
|
Press Release
| $3.38 $3.54 | ▲ +4.73% | ▲ +4.17% | $3.92 (+15.98%) |
|
Mar 17, 2026
12w ago
|
Press Release
| $3.65 $3.56 | ▼ −2.47% | ▼ −1.07% | $3.92 (+7.40%) |
|
Mar 10, 2026
13w ago
|
Press Release
| $4.14 $4.06 | ▼ −1.93% | ▼ −1.83% | $3.92 (−5.31%) |
|
Mar 6, 2026
14w ago
|
Press Release
| $3.39 $3.89 | ▲ +14.75% | ▲ +13.90% | $3.92 (+15.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access